Why are investors buying into Oxford Biomedica (LN:OXB)? In this interview, BBC broadcaster Vivienne Parry OBE asks CEO John Dawson why Oxford Biomedica is so much more than a manufacturer of the AstraZeneca vaccine, which has propelled the company into the limelight. Watch now.
See more content on Oxford Biomedica here.
Oxford Biomedica (LN:OXB) is a global leader in cell and gene therapy. It has expanded its manufacturing facilities through Oxbox, an 84,000 sq ft state-of-the-art bioprocessing facility, significantly increasing its production capacity to match demand and to continue growing its revenues. In the near term, revenues will continue to be driven by the Novartis partnership for CAR-T Kymriah as the commercial roll-out continues and by the manufacturing agreement it has with AstraZeneca for its COVID-19 vaccine. OXB has established many cell and gene development and manufacturing partnerships, including with Novartis, Juno Therapeutics (BMS), Bioverativ (Sanofi), Orchard Therapeutics, Sio Gene Therapies, Boehringer Ingelheim, Santen, Beam Therapeutics and PhoreMost. OXB also has an 18-month supply agreement with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.